Top Stock Movers Today — July 29, 2026: Why MWYN, VRRM, MPLT & MANH Surged

MWYN — Marwynn Holdings, Inc. (+31.8%)

Marwynn Holdings closed up 31.8% to $0.65 on volume of 29.0 million shares — roughly 18× its 20-day average of 1.57 million. For a micro-cap Consumer Discretionary name with a market cap of just $13.0 million, that kind of volume surge can move the price dramatically in a single session. The stock also gapped up 20.4% at the open, meaning much of the day's gain was baked in before most retail traders had a chance to react. A gap occurs when a stock's opening price is meaningfully above (or below) the prior close, often reflecting overnight news or order imbalance.

No specific catalyst is on file — there were no relevant recent headlines, and the only recent SEC filing was a routine neutral 8-K filed July 15. With no clear fundamental driver, this move looks momentum- and technically-driven, likely amplified by the stock's tiny size and the extreme volume surge attracting short-term traders.

The technical picture is mixed at best. The day's candle printed a bullish harami — a two-candle pattern where a small bullish body is "contained" inside the prior session's larger bearish body, hinting that selling pressure may be stalling. But context matters: the RSI (Relative Strength Index, a 0–100 momentum gauge) sits at just 37, below the neutral 50 level, and the stock remains 53.2% below its 52-week high. The MA (moving average) stack is mixed, the ADX of 37 suggests a moderately trending environment, and StockSetups' conviction score is a low 34/100 with a D grade.

Short-squeeze potential here is limited. The squeeze score is 26/100, and while short-volume ran at 51% of today's trading, short interest is tiny at just 70,592 shares with only 0.5 days to cover (days to cover = short interest divided by average daily volume; a low number means shorts can exit quickly without moving the stock). MWYN is a highly speculative, low-priced micro-cap — moves of this size can evaporate just as fast as they appear.

VRRM — Verra Mobility Corp (+22.6%)

Verra Mobility surged 22.6% to $5.13, closing on volume of 33.6 million shares — more than 6× its 20-day average of 5.6 million. The stock gapped up a striking 37.6% at the open, a huge overnight move for a $778.5 million market-cap Consumer Discretionary company that provides smart transportation technology.

The catalyst: On July 28, Yahoo Finance reported that Verra Mobility reached a framework agreement with Avis Budget Group. That headline drove the overnight gap and the heavy buying. Details beyond the agreement's existence are not available in the data, but a major commercial partnership announcement is clearly what lit the fuse here.

Despite the big move, the technical backdrop carries caution flags. The stock's MA stack is bearish — meaning its shorter-term moving averages are still below longer-term ones — and it remains 79.9% below its 52-week high, indicating this name had been in a severe downtrend. The RSI of 59 is neutral-to-firming after the surge, and the ADX of 36 reflects a trending day. StockSetups' conviction score is a weak 24/100 (grade D), and the RS (relative strength) rating is just 1 out of 99 — the stock had dramatically underperformed the market before today.

The short-squeeze angle is worth noting: the squeeze score is 52/100, short interest stands at 10.99 million shares, and days to cover is 2.5 — moderate pressure. Short-volume ran at 54% today, suggesting shorts were active but the news-driven buying overwhelmed them. Reddit buzz was picking up (rank #51 on r/all-stocks with 17 mentions). With a stock still so far from its 52-week high and a mixed technical structure, the sustainability of this move hinges entirely on whether that Avis Budget framework becomes a fully executed, revenue-generating deal.

MPLT — MapLight Therapeutics, Inc. (+22.1%)

MapLight Therapeutics closed up 22.1% to $15.03 on volume of 6.39 million shares — more than 4× its 20-day average of 1.48 million. The move came in the context of an extraordinary two-day story: just two days prior, MPLT had crashed 73% after a clinical trial disappointment, wiping out over $1 billion in market cap.

The full picture: On July 27, MapLight announced positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia — the drug hit its primary endpoint. However, that same day the stock collapsed 73%, suggesting the market reacted to a separate miss (likely on the once-daily dosing formulation, per a Stocktwits headline that noted "MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose"). Today's +22.1% bounce appears to be a partial recovery as investors reassessed the positive Phase 2 headline and the stock's now-compressed valuation after the prior day's wreckage. The stock closed at $15.03 — still 62.3% below its 52-week high — showing just how much value was destroyed.

The short-squeeze angle here is compelling. MPLT carries a squeeze score of 94/100 — among the highest possible. A short squeeze occurs when heavily shorted shares rise in price, forcing short sellers (who profit when a stock falls) to buy shares to close their positions, which accelerates the rally. The free float (the portion of shares freely tradeable by the public) is a tight 41.1%, short interest is 3.59 million shares, and days to cover is 6.7 — meaning it would take more than six average trading days for all shorts to exit. Short-volume was a very elevated 64% of today's activity. With a tight float and high short interest, even modest buying can send the stock sharply higher.

Adding a bullish signal: insider Cox Troy purchased 15,620 shares ($149K) on July 28 — the day after the crash — a Form 4 buy that signals at least one company insider saw value at beaten-down levels. The RSI of 30 is near oversold territory (below 30 is traditionally "oversold"), and the ADX of 42 confirms strong momentum in the current move. StockSetups' conviction score is 43/100. MPLT remains a high-risk biotech recovery play; clinical-stage drug names can be exceptionally volatile, and a bounce after a 73% drop does not guarantee a sustained recovery.

MANH — Manhattan Associates, Inc. (+21.7%)

Manhattan Associates closed up 21.7% to $204.58 on volume of 5.48 million shares — more than 5× its 20-day average of 972K. This is the highest-quality name in today's group: a $12.1 billion market-cap Technology company that makes supply chain and omnichannel commerce software.

The catalyst: Manhattan Associates filed an earnings 8-K with the SEC on July 28, confirming Q2 earnings results. The market's reaction — a 21.7% surge with a 14.8% gap up at the open — tells us the results clearly came in well ahead of expectations, though specific revenue or EPS figures are not in the data. Analysts had been previewing the report closely (multiple preview stories ran on July 27), and the decisive market reaction suggests a strong beat and likely raised guidance.

This is fundamentally a different profile from the other movers today. The MA stack is mixed but MANH sits only 10.3% below its 52-week high — far less damaged than the others. The RSI of 78 is elevated (above 70 is traditionally considered "overbought"), reflecting the strength of today's surge, and the ADX of 21 suggests the trend is still developing. Most notably, StockSetups rates MANH with a conviction score of 77/100 and a grade A — the highest in today's group — with a perfect trend-template score of 5/5 and an RS rating of 82, meaning it had already been outperforming 82% of the market before today's move. The technical rank of 93 reinforces that picture.

The short-squeeze angle is secondary here. The squeeze score is 48/100, with 2.87 million shares short and 4.2 days to cover. Short-volume was a lower 44% today, consistent with a genuine fundamental-driven move rather than a squeeze. This is an earnings-driven gap on a large-cap, high-quality compounder — a meaningfully different risk profile than the micro-caps above, though buying any stock up 21.7% in a single day still carries the risk of chasing an extended move.

The bottom line

Today's four biggest gainers — MWYN, VRRM, MPLT, and MANH — all surged 20% or more, but for very different reasons: an unexplained momentum spike in a micro-cap, a major commercial agreement, a post-crash short squeeze in a biotech, and a strong earnings beat from an enterprise software leader. They also carry very different risk profiles.

A few honest reminders before you do anything with this information:

• Big one-day gains frequently reverse. Stocks that surge 20–30% in a session often give back a significant portion of those gains in the days that follow, especially when the move was momentum- or squeeze-driven rather than a durable fundamental change.
• Extended RSI readings matter. MANH's RSI of 78 and MWYN's gap of 20%+ at the open are signs of short-term extension — chasing stocks at these levels is high-risk.
• Squeezes unwind. A high squeeze score (like MPLT's 94/100) means shorts could be forced to cover, amplifying gains — but once covering is done, the buying pressure evaporates. [figure:short-interest]
• Do your own research. Nothing here is financial advice or a recommendation to buy or sell any security. Always size your risk appropriately.

StockSetups scans the full ~12,300-stock US universe after every close, detecting chart patterns, scoring conviction, and surfacing setups like these across four lanes — setting up, breaking out, broke out, and retesting. Check back tomorrow for the next recap, and see how today's moves set up for what comes next.

Previously on StockSetups: Top Stock Movers Today — July 24, 2026: Why NIPG & RNG Surged · Top Stock Movers Today — July 23, 2026: Why WLDS, WBUY, YOUL, NVCR & DOMO Surged